| Literature DB >> 25999952 |
Sinem Esra Sahingur1, W Andrew Yeudall2.
Abstract
The chemotactic cytokines, or chemokines, comprise a superfamily of polypeptides with a wide range of activities that include recruitment of immune cells to sites of infection and inflammation, as well as stimulation of cell proliferation. As such, they function as antimicrobial molecules and play a central role in host defenses against pathogen challenge. However, their ability to recruit leukocytes and potentiate or prolong the inflammatory response may have profound implications for the progression of oral diseases such as chronic periodontitis, where tissue destruction may be widespread. Moreover, it is increasingly recognized that chronic inflammation is a key component of tumor progression. Interaction between cancer cells and their microenvironment is mediated in large part by secreted factors such as chemokines, and serves to enhance the malignant phenotype in oral and other cancers. In this article, we will outline the biological and biochemical mechanisms of chemokine action in host-microbiome interactions in periodontal disease and in oral cancer, and how these may overlap and contribute to pathogenesis.Entities:
Keywords: Toll-like receptor; chemokine; host–pathogen interactions; inflammation; oral cancer; periodontitis
Year: 2015 PMID: 25999952 PMCID: PMC4419853 DOI: 10.3389/fimmu.2015.00214
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Chemokine structure. (A) Schematic indicating the relationships between conserved cysteine residues (C), together with intrachain disulfide bridges. C-, CC-, CXC-, and CX3C- classes of chemokines are depicted. (B) Schematic representation of human CXCL5, a pro-inflammatory and pro-angiogenic ELR+ chemokine, which contains the ELR motif N-terminal to the CXC consensus sequence.
Studies investigating the link between oral cancer and periodontal disease.
| Author | Study design | Oral health criteria | Study population | Results |
|---|---|---|---|---|
| Bundgaard et al. ( | Case-control | Missing teeth | 161 patients and 400 controls (Denmark) | Significantly increased risk of developing oral SCCA for patients with fewer than 15 teeth |
| Rezende et al. ( | Case-control | CPITN | 50 patients and 50 controls (Cuba) | 76% of subjects in cancer group showed greater than 6 mm pockets compared to 10% of control group |
| Garrote et al. ( | Case-control | Missing teeth | 200 patients and controls (Cuba) | Significantly increased risk of oral cancer for patients missing 16 or more teeth |
| Hiraki et al. ( | Case-control | Missing teeth | 429 patients and 10,480 controls (Japan) | Significantly increased risk of head and neck cancer with decreased number remaining teeth |
| Marshall et al. ( | Case-control | Missing teeth | 290 patients and controls (United States) | Significantly increased risk of oral cancer with loss of 11 or more teeth |
| Michaud et al. ( | Cohort | Self-reported history of periodontal disease (confirmed by radiographs and missing teeth) | 118 patients (United States) | No significant increase in risk for oropharyngeal cancer with history of periodontal disease or increased number of tooth loss |
| Rosenquist et al. ( | Case-control | Missing teeth | 132 patients and 320 controls (Sweden) | Significantly increased risk of oral and oropharyngeal cancer for missing over 20 teeth |
| Tezal et al. ( | Cohort | Clinical attachment loss (CAL) | 131 oral tumors and 323 oral pre-cancerous lesions (United States) | Significantly increased risk of oral tumor and pre-cancerous lesion with >1.5 mm clinical attachment loss |
| Tezal et al. ( | Case-control | Alveolar bone loss | 51 cases and 54 controls (United States) | Significantly increased risk of tongue cancer with increased alveolar bone loss |
| Tezal et al. ( | Case-control | Alveolar bone loss | 266 patients and 207 controls (United States) | Significantly increased risk of oral cavity SCC with periodontitis |
| Tezal et al. ( | Case-control | Alveolar bone loss | 124 head and neck SCC patients (United States) | Periodontitis is associated with tumor HPV status |
| Wen et al. ( | Cohort | Medical records from insurance claims | 96,375 gingivitis and 51,791 periodontitis cases (Taiwan) | Significantly increased risk of oral cancer with the history of periodontitis |
| Zheng et al. ( | Case-control | Missing teeth | 404 subjects and controls (United States) | Significantly increased risk of oral cancer with increased missing teeth |
.
.
Figure 2Factors contributing to periodontitis and cancer. Flow diagram outlining the interplay between host and environmental factors that modify the oral microenvironment, contribute to periodontitis and oral cancer, and which may link the two diseases.
Figure 3Plausible biological mechanisms that may link deregulated inflammation and cancer. Engagement of microbial components (LPS, lipoproteins, nucleic acids) or damage-associated molecular patterns (DAMPs) with their receptors (TLRs) triggers activation of inflammatory signaling cascades and increases production of inflammatory mediators, tissue destructive enzymes (MMPs), and reactive oxygen/nitrogen species. Accumulation of these host-derived factors within the mucosa due to deregulated inflammation may alter and create a favorable oral microenvironment that promotes tumorigenesis.
Figure 4Key chemokine functionalities in periodontitis and oral carcinogenesis. A dysbiotic oral microflora triggers inflammatory processes in the oral epithelium. Release of chemokines, among other molecules, results in progression (or suppression, in some cases) of the inflammatory process and stimulation of both innate and adaptive immune responses through recruitment of cellular mediators. Persistent inflammation extends deeper into the tissues, subsequently leading to osteoclast activation and subsequent destruction of alveolar bone. Multiple chemokines involved in the periodontal inflammatory process may stimulate their cognate receptors present on normal, dysplastic, or malignant epithelial cells, deregulating cellular growth, and promoting the motile phenotype. Pro-angiogenic chemokines, such as IL-8 and CXCL5, act upon endothelial cells to promote neovascularization of developing tumors. LN, lymph node; ROS, reactive oxygen species; PMN, neutrophil polymorph; OCP, osteoclast precursor; DC, dendritic cell; MΦ, macrophage.